A TWO STEP INDUCTION OF INDOLEAMINE 2,3 DIOXYGENASE (IDO) ACTIVITY DURING DENDRITIC CELL MATURATION

Introduction
Prostaglandin E 2 (PGE 2 ) is a catabolite of arachidonic acid and is generated by the sequential activity of cyclo-oxygenase (COX) and prostaglandin E synthase 1 . Produced during inflammation, PGE 2 is believed to act as a counter-inflammatory agent, modulating inflammatory responses and helping to restore tissue homeostasis. For example, PGE 2 has been reported to suppress T cell proliferation 2, 3 , inhibit macrophage and dendritic cell cytokine production (e.g. interleukin (IL)-12 and TNFα 4, 5 ) and modulate antigen presentation by downregulating expression of MHC II 6 . Additionally, PGE 2 may skew CD4 + T cells toward a T H 2 phenotype 7, 8 and B cells toward IgE production 5 . In other studies, PGE 2 has been shown to play a role in T cell development 9 and may be an inhibitor of apoptosis in double-positive thymocytes 10 . Consistent with these reports, expression of various prostaglandin biosynthetic enzymes and receptors has been detected in the thymus 11 . Dendritic cells (DCs) are considered to be the only antigen presenting cell (APC) capable of priming naïve T cells, and are also potent stimulators of recall responses 12 . Briefly, DCs exist in the periphery as immature cells where they serve as 'sentinels,' responsible for capturing antigen. Upon maturation, DCs migrate to the draining lymphoid organs, where they may initiate immune responses. This ability to traffic out of peripheral tissue with captured antigen, and enter the afferent lymph is unique to the DCs, making them the appropriate carrier of tissue-restricted antigen to lymphoid organs for the initiation of immunity 12 . Their role in priming T cells has also prompted much interest in discovering strategies to efficiently employ DCs carrying tumor antigen for adoptive transfer and immunization of tumor-reactive T cells. Our understanding of DC biology, however, has not resulted in overwhelming success-few DC-based studies have reported an effect greater than the 10% rate achieved by Coley [13] [14] [15] . Given that DCs are capable of mediating both T cell priming as well as T cell inactivation (tolerance)-a deeper understanding of how to counter DC tolerogenic programs may advance our efforts to achieve tumor immunity. One area of active investigation has been the definition of maturation programs for DCs, in an attempt to obtain large numbers of stimulatory DCs for purposes of immunotherapy.
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Based on careful studies analyzing T cell stimulatory capacity, cell yield, DC migration studies and safety concerns, the majority of DC-based trials utilize GMP-grade cytokines cocktails (e.g. TNFα, IL-1β, IL-6 and PGE 2 ) for the ex vivo maturation of monocyte-derived immature DCs. The principle reason for the addition of PGE 2 is based on the observation that it regulates the migratory capacity of DCs by sensitizing CCR7 to its ligands, CCL19 and CCL21 16, 17 . Additionally, PGE 2 enhances the effect of the maturation cocktail, making it possible to utilize 20-100 times less TNFα 18 . In further support of its use, DCs matured in the presence of PGE 2 show no defect in the generation of phenotypically mature DCs, the priming of naïve allogeneic T cells or the stimulation of antigen-specific CD4 + and CD8 + T cell responses 19, 20 . In prior studies, we have employed TNFα and PGE 2 in order to mature DCs. Such cells possess the ability to both prime and tolerize CD8 + T cells, depending on the immune context and the route by which antigen is processed and presented 21 . Indoleamine 2,3-dioxygenase (IDO) is an enzyme involved in tryptophan catabolism. Its role in antimicrobial resistance is well described; by actively depleting tryptophan, essential for the growth of microorganisms, both within the infected cell and in the surrounding milieu, IDO serves to suppress growth of invasive bacteria. More recently, it has been established that IDO regulates maternal tolerance and possibly more general aspects of T cell tolerance [22] [23] [24] [25] [26] . IDO expression has been reported in placental trophoblasts and IFNγ activated APCs (including macrophages and DCs), reflecting its counter-inflammatory role. An exciting advance for this field has been the discovery that IDO is initially expressed as a pro-enzyme. While little is known regarding the biochemical signals responsible for transcriptional activation of the IDO gene, it has been shown that reverse signaling via B7 (CD80 / CD86), as well as engagement of CD200R, serve to regulate IDO enzyme activity [27] [28] [29] . Herein, we characterize the mechanism by which IDO is upregulated in monocytederived DCs. We report that that PGE 2 induces mRNA expression of IDO, however, the enzyme remains inactive. Only in response to a second signal via TNF-R or TLR do we observe bioactive IDO. Surprisingly, use of TNFα, lipopolysaccharide or SAC alone does not induce IDO. This study offers new insights into the immune-modulatory effects of PGE 2 as well as provides a better understanding as to how IDO expression is achieved in inflammatory situations. Importantly, this work will impact the design of future DC-based immunotherapy trials.
Materials and Methods
Human subject materials. Human blood components were obtained from normal donors (EFS, Rungis). Materials were stripped of patient identifiers and shipped to Institut Pasteur in accordance with institutional policy (#HS2003-5720) and the tenets of the Helsinki protocol.
Reagents. TNFα (Endogen, Boston, MA) was used at a concentration of 100ng/ml and PGE 2 (Sigma, St Louis, MO) at 5µM, unless otherwise stated. LPS, serotype 055;B5 (Sigma) was sonicated and used at 50ng/ml, Staphylococcus aureus Cowan I strain (SAC) was used at 0.0025% wt/vol (Pansorbin, Calbiochem-Behring, LaJolla, CA). L-Tryptophan, L-Kynurenine and Forskolin (Sigma) were used as described below; EP1, EP3 and EP4 agonists (L-335677, L-826266 and L-161982 respectively) were provided by Merck Frost & Co (Canada) and used at a concentration of 50µM; Butaprost and 19(R)-OH PGE 2 (EP2 agonists), sulprostone (EP1>>3 only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From agonist) were obtained from Cayman Chemicals, Ann Arbor, MI, USA and used at 0.5 -250µM. The adenylate cyclase inhibitor SQ22536 (Biomol international, LP) was titrated and the optimal concentration to inhibit forskolin was found to be 1mM. H-89 (Sigma) was used at 10-50µM for the inhibition of protein kinase A (PKA).
Isolation and preparation of dendritic cell. Monocyte-derived DCs were prepared as described. Briefly, buffy coats were obtained from normal donors and peripheral blood mononuclear cells (PBMCs) were isolated by sedimentation over Ficoll-Hypaque (Pharmacia Biotech, Piscataway, NJ). CD14-enriched and CD14-depleted fractions were prepared using CD14 Miltenyi microbeads followed by magnetic cell sorting according to the manufacturers' instruction (Miltenyi Biotech, Auburn, CA). Immature DCs were prepared from the CD14 + fraction by culturing cells in the presence of GM-CSF (Berlix, Seattle, WA) and IL-4 (R&D Systems, Minneapolis, MN) for 7 days. GM-CSF (1000U/ml) and IL-4 (500U/ml) were added to the cultures on days 0, 2 and 4. To generate mature DCs, the cultures were transferred to fresh wells on days 6-7 and the indicated maturation stimulus was added for an additional 1-2 days. At days [6] [7] TM detector (MJ Research, MA, USA). The analyses were performed with the Opticon Monitor TM software version 2.03. All the measures were performed in duplicates and validated when the difference in Ct between the 2 measures was less than 0.3. Amplification and dissociation curves of increasing amounts of total PBMC cDNA allowed validation of our assay; and dissociation curves displayed a single peak, ruling out the presence of primer dimers or parasitic products (Supplementary Figure 1A) . The ratio gene of interest/ housekeeping genes was calculated according to the formula: ratio=2 -dCt (dCT= mean Ct gene -mean Ct housekeeping). GAPDH and TBP were used to normalize for IDO and EP-receptor mRNA expression, respectively.
Detection of IDO protein expression. Cell lysates were prepared from 10 6 DCs using RIPA buffer (20mM Tris pH7,5, 150mM NaCl, 10%Glycerol, 1% Nonidet P-40, Complete ® (Roche, protease inhibitor cocktail)). One third of the total protein lysate was separated on 12% or 14% SDS-PAGE. After transfer to PVDF membranes, protein loading was monitored using Ponceau Red staining. IDO protein was detected using a rabbit polyclonal Ab preparation (generous gift of David Munn, Medical College of Georgia, Augusta, GA) and anti-rabbit IgG-HRP (Santa Cruz Biotechnology, Santa Cruz, CA), and visualized by chemiluminescence (ECL, Amersham).
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From Determination of IDO enzymatic activity. To monitor enzyme activity, DCs were washed and resuspended in Hanks Buffer (HBSS) containing 100µM tryptophan (Life Technologies) and incubated for 4hr. Supernatants were harvested and assayed for the presence of kynurenine, the first stable catabolite downstream of IDO. Kynurenine was detected by either high-pressure liquid chromatography (HPLC) or using a modified spectophotometric assay. HPLC was performed according to Young and Lau 31 with minor modifications. Briefly, 40µl of the clarified sample was injected into an Amersham reverse phase C2/C18 column and eluted with KH2PO4 buffer (0.01M KH2PO4 and 0.15mM EDTA, pH 5.0) containing 10% methanol at a flow rate of 1.0 ml/min. The spectrophotometer was set at 254nm to detect both kynurenine and tryptophan. Retention time was determined empirically using standard solutions of kynurenine and tryptophan. IDO activity is reported as the concentration of kynurenine produced. Alternatively, kynurenine were measured spectrophotometrically 32, 33 . 50µl of 30% trichloroacetic acid was added to 100µl of the culture supernatant, vortexed and centrifuged at 10,000 rpm for 5min. 75µl volume of the supernatant was then added to an equal volume of Ehrlich's reagent (100 mg of pdimethylbenzaldehyde, 5ml of glacial acetic acid) in a microtiter plate well (96-well format). Optical density was measured at 492-nm using a Multiskan MS (Labsystems) microplate reader. A standard curve of defined kynurenine concentration (0-100µM) permitted analysis of unknowns.
Results
IDO expression and activity are upregulated during DC maturation.
The phenotypic and functional changes that occur during DC maturation are critical for generating MHC/peptide complexes and engaging T cells, however, the molecular definition of distinct maturation programs has only recently been considered. As previously reported by others 34 , we analyzed the transcriptional profile of monocyte-derived DC at the various stages of differentiation using Affymetrix gene arrays (Longman and Albert, unpublished data). Strikingly, we observed a >100 fold increase in expression of indoleamine 2,3-dioxygenase (IDO) as a result of DC maturation. This has been reproduced in 4/4 donors and the relative signal intensity of IDO mRNA expression is shown, using GAPDH expression as an internal reference ( Figure 1 ).
Based on IDO's proposed role in immune tolerance, we evaluated the effect of different DC maturation stimuli on IDO expression. Despite some published data in this area [35] [36] [37] , a thorough assessment of the expression and activity of IDO as influenced by DC maturation had yet to be performed. We first established assays to monitor IDO mRNA expression using realtime quantitative RT-PCR (qPCR), and Western blot. RNA was extracted from immature DCs (iDC) exposed to distinct maturation stimuli and IDO expression was quantified as described in the Materials and Methods. Consistent with our chip studies, iDCs matured with TNFα and PGE 2 upregulated IDO mRNA (Figure 2A ). In contrast, iDCs exposed to LPS or SAC did not express measurable levels of IDO mRNA. Evaluation of cell lysates using an IDO rabbit pAb (generously provided by Dr. David Munn, University of Georgia) showed good correlation between protein expression and the mRNA levels ( Figure 2B ).
In addition, it was important to monitor IDO enzymatic activity as there has been a reported discrepancy between IDO expression and activity, suggesting possible post-translational regulation of the enzyme 35, 38 . IDO activity may be assayed by quantifying tryptophan catabolism as well as the generation of kynurenine (the first catabolite in the metabolic pathway). After 36-only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From 48hr of exposure to the distinct maturation stimuli, the DCs were cultured in HBSS containing 100µM tryptophan. After 4hrs, the concentration of tryptophan and kynurenine was determined by high-pressure liquid chromatography (HPLC). As shown, the two products can be easily separated and the area under the curve correlates with the amount of the respective analyte (Supplementary Figure 2A) . Notably, we observed robust enzyme activity in DCs matured with TNFα and PGE 2 but no evidence of tryptophan catabolism was detected in iDCs, LPS-or SACmatured DCs ( Figure 2C ). In our initial studies, IFNγ exposed DCs served as a positive control for IDO expression and activity. DCs matured from multiple individuals permitted evaluation of donor variability (Table 1) .
Due to our interest in monitoring IDO functional activity in several conditions for DC stimulation, we took advantage of a medium-throughput (96-well assay) colorimetric assay for monitoring kynurenine 33 . To validate this approach, we established a standard curve for quantifying kynurenine and compared the experimental values obtained using the colorimetric assay with those from the HPLC analysis. A strong correlation was observed (Supplementary Figure 2B-D) , thus allowing us to utilize the colorimetric assay for monitoring IDO activity.
Prostaglandin E 2 is responsible for the expression of IDO mRNA. In an attempt to define the stimuli responsible for IDO expression, we revealed a surprising result. Similar to treatment of iDCs with LPS or SAC, when used alone TNFα did not upregulate IDO expression. Instead, it was exposure of PGE 2 that accounted for expression of IDO mRNA ( Figure 3A, B) . While we observed a 50-200 fold increase in transcription of IDO, PGE 2 treated DCs lacked measurable IDO activity ( Figure 3C ).
This finding suggests that while PGE 2 induces transcription of the IDO gene, a second signal, such as exposure to TNFα, is required to achieve active IDO enzyme. Similar to TNF-R engagement, TLR ligation also induced IDO activity when used in combination with PGE 2 ( Figure. 4A, B) . Characterization of the pAb used suggests that it may be selective for active enzyme (data not shown); consequently, we are unable to determine if TNF-R / TLR-regulates a transcriptional or post-transcriptional event. What is clear from our data, based on Figures 2-4 , is that there exists a two-step regulation of IDO activity during DC maturation.
Signaling via EP2 triggers IDO expression. Eight human prostanoid receptors have been described, of which four bind PGE 2 with high affinity (K d in the low nM range). Of these four receptors, EP1 and EP3 are coupled to inhibitory G proteins; whereas EP2 and EP4 signal via stimulatory G proteins. Based on our micro-array data and published studies 39 , only EP2 and EP4 are expressed by monocyte-derived DCs (data not shown). We validated these findings in our culture system using quantitative RT-PCR. As shown, iDCs express higher levels of EP2 and low levels of EP4. After exposure to TNFα and PGE 2 , the pattern of expression is reversed ( Figure. 5A ). Of note, PGE 2 seems to be responsible for the down-regulation of EP2, whereas both TNFα and PGE 2 are required to observe upregulation of EP4.
Next, we evaluated which EP receptor mediates IDO expression. This was done functionally, by exposing iDCs to agonists specific for EP1-4 in the presence of TNFα and IDO activity was measured as described above. In 3/3 individuals, only the EP2 agonist butaprost resulted in the induction of IDO activity ( Figure. 5B) . As EP2 is a Gαs-coupled receptor, we tested if ectopic activation of adenylate cyclase would mimic the effects of a receptor agonist. When iDCs were treated with the adenylate cyclase activator forskolin in combination with TNFα, the IDO activity was equivalent to that in TNFα and PGE 2 matured DCs ( Figure 6A 
directly tested the effect of adding either an inhibitor of adenylate cyclase or the cAMPtriggered kinase PKA on the mRNA expression of IDO. As shown, both inhibitors decreased the PGE 2 -and forskolin-induced expression of IDO. Together, these results suggest that during DC maturation, PGE 2 acts through the EP2 receptor expressed on iDC, which in turn activates adenylate cyclase leading to PKA activation and an increase in the transcription of the gene coding for IDO. The presence of a TNF-R or TLR agonist enhances expression and importantly, this second signal facilitates IDO enzymatic activity.
Discussion
A novel mechanism by which PGE 2 modulates the immune system. Like many effectors of immune regulation, the actions of PGE 2 are complex and in some instances at apparent odds. With respect to its effect on T cells, the data indicates that PGE 2 inhibits proliferation and skews responses toward T H 2 differentiation 2, 7, 40 . And while inhibition of TNFα, IL-6 and IL-12p35 in antigen presenting cells would be consistent with a suppressive role for PGE 2 4,41 , recent studies indicate a pro-inflammatory activity of PGE 2 , based on the induction of bio-active IL-23 42, 43 . PGE 2 has also been shown to act as a survival signal for thymocytes and may be critical for T cell development 10 . Furthermore, PGE 2 is critical both for the generation of migratory DCs: monocyte-derived DCs demonstrate poor migration potential to CCR7 ligands unless matured in the presence of PGE 2 16 ; and in vivo, it has been demonstrated that mouse Langerhans cell migration to the draining lymph node is dependent on PGE 2 signaling via EP4 44 . The stimulation of DC migration has been interpreted as pro-inflammatory, as migratory DCs are required for the trafficking of antigen to the T cell area of lymph nodes, thus permitting the initiation of an immune response 43 . We report a novel mechanism by which PGE 2 acts to counter inflammatory responses. Our study indicates that PGE 2 induces mRNA expression of IDO by signaling via the Gs-protein coupled receptor EP2. This in turn activates adenylate cyclase, catalyzing the formation of cAMP and activating PKA. Evidence to support this mechanism is provided by the use of EPreceptor analogs and the demonstration that the EP2 agonist, butaprost, was alone in its ability to mimic the effects of PGE 2 ( Figure 5) . Additionally, we demonstrate that direct stimulation of adenylate cyclase triggered IDO expression; whereas, treatment with an adenylate cyclase inhibitor or a PKA inhibitor blocked EP2 signaling and inhibited PGE 2 -mediated induction of IDO ( Figure 6 ). While this pathway accounted for a 50-200 fold increase in IDO expression, to our surprise, PGE 2 treated DCs displayed no active IDO enzyme as monitored by the catabolism of tryptophan. Only when combined with a second signal via TNF-R or a TLR, did we observe the production of kynurenine (Figures 2-4) . Although use of TNFα, lipopolysaccharide or SAC alone does not induce IDO, they are required to trigger enzymatic activity in PGE 2 -treated DCs. These findings offer the first innate effector pathway for the activation of IDO and suggest a link between DC migration and the acquisition of mechanisms for immune tolerance. Indeed, such a connection pushes one to consider the possibility that migratory DCs are programmed so that its' default pathway is tolerance.
Activation of indoleamine 2,3-dioxygenase. The actions of IDO offers an intriguing mechanism for achieving T cell tolerance (reviewed in 23)-it catabolizes the essential amino acid tryptophan, resulting in the generation of a putative pro-apoptotic agent, kynurenine, as well as other downstream immunomodulatory metabolites 45, 46 . IDO expression by human monocyteonly.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From derived DCs and macrophages potentiates the ability of these cells to inhibit T cell proliferation. Furthermore, a role for IDO has been shown critical in achieving maternal tolerance, suppression of T cells reactive to haplotype-mismatched allografts and the control of auto-reactive T cells 23 . More recently, it was demonstrated that the ectopic expression of IDO in tumor cells confers immune evasion 47 . While there is strong support for IDO's role in mediating T cell tolerance, less is known about the regulation of IDO expression and the mechanism of enzyme activation. The only characterized trigger of IDO expression is IFNγ. It has been demonstrated in some cell types, that IFNγ-induced gene expression can be enhanced or antagonized when added in combination with other cytokines. For example in eosinophils, it has been demonstrated that GM-CSF synergizes with IFNγ, while IL-3 antagonizes IFNγ-mediated IDO expression 48 . With respect to stimulators of IDO activity, they include CTLA-4 and CD28, which have been shown to transmit signals to the DC by cross-linking the co-stimulatory molecules B7-1 / B7-2 27 . Of note, IFNγ also appears capable of achieving active IDO enzyme, however, its contribution may need to be re-evaluated in light of data for B7-reverse signaling 49 . If we are to interpret the findings that IFNγ and B7-reverse signaling are critical for IDO activation, it appears that stimulation of the adaptive immune system is required in order to achieve tolerance of the adaptive immune system. In identifying PGE 2 as a trigger for IDO expression, we offer a novel means by which the innate immune system may regulate T cell immunity.
While previous studies have demonstrated the possibility of post-translational control for IDO 48, 50 , we are unable to conclude if our observation that TNF-R and TLR ligands are required for achieving enzymatic activity is reflective of translational control or a still undefined posttranslational event. Nonetheless, our results help to clarify the signals responsible for IDO expression and activity in monocyte-derived DCs. Given the interest in using DCs for clinical immunotherapy and the sensitivity of IDO expression to the culturing conditions 51, 52 , we hope that our findings will help clarify some of the differences observed in the various systems that are currently in use.
Implications for DC-based immunotherapy.
With respect to DC-based immunotherapy protocols, it is important to note that many utilize maturation cocktails containing PGE 2 . As discussed above, this is in part due to its role in sensitizing DCs to CCR7 ligands, thus enhancing DC migration to the draining lymph nodes. Our finding that PGE 2 is also sensitizing DCs to TNFα-mediated IDO activation predicates caution, as we may be inducing the opposite of what is intended. One consideration is the segregation of the distinct effects of PGE 2 . Migration appears to be mediated by EP4, while IDO gene expression occurs in response to EP2 stimulation. Use of EP4-specific agonists may allow such a separation to be achieved. Alternatively, it may be possible to include an IDO inhibitor in the DC maturation cocktail, thus generating a mature, CCR7-responsive DC with an inactive IDO enzyme.
In sum, our findings illustrate a novel role for PGE 2 and important insight into the regulation of IDO. With a better understanding of these regulatory mechanisms and the cross-talk between TNF-R / TLR and EP2 signaling pathways we hope to uncover new insight into the regulation of T cell activation by DCs and the interplay between tumors and the immune system. The PCR amplification curves from a representative experiment, performed in duplicate, are displayed (A). The same data is reported as a ratio of IDO/GAPDH, again normalized to expression in iDCs (set to a value of 1.0). The inset in (B) represents the level of IDO mRNA as a function of the dose of PGE 2 . (C) DCs exposed to the conditions described above were monitored for their IDO activity. Kynurenine production was measured using a colorimetric assay; known concentrations were used for the establishment of a standard curve (see Supplementary Figure 2B We monitored EP2 and EP4 mRNA expression in DCs exposed to TNFα, PGE 2 or a combination of both stimuli. TBP was used as a reference for our qPCR studies as its expression levels matched that of the EP-Rs. White bars represent EP2 levels; black bars indicated EP4 expression. Of note, no message could only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From be detected for EP1 and EP3 by qPCR (data not shown). (B) PGE 2 was replaced by different EP agonists during DC maturation and IDO activity was assessed after 48hrs. L-335677, Butaprost, L-826266 and L-161982 were used to stimulate EP1-4, respectively. All were used at a concentration of 50µM. In similar experiments, sulprostone was used as an EP1 >> EP3 agonist and 19R-hydroxy PGE 2 as an EP2 agonist, with similar results (data not shown). 
